Elevance Health, Inc.

Elevance Health, Inc. (ELV) announced that its officers will reaffirm the company's full year 2026 earnings guidance during investor meetings. Shareholders' earnings are expected to be at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items. Excluding these items, adjusted shareholders' earnings are projected to be at least $29.00 per diluted share. The company also reaffirmed its full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.

Elevance Health reported mixed results for Q2 2026, with total revenues increasing to $50.47 billion from $49.78 billion year-over-year. However, diluted earnings per share decreased to $6.71 from $7.72 in the prior year period. The company initiated an Operating Model Transformation Program, incurring $129 million in costs during the first six months of 2026, which impacted profitability. Despite this, net cash provided by operating activities significantly increased to $6.25 billion for the six-month period.

Elevance Health reported second-quarter 2026 results ahead of expectations, with operating revenue of $49.8 billion, an increase of 0.8% year-over-year. The company achieved diluted EPS of $6.71 and adjusted diluted EPS of $7.45. Reflecting strong performance, Elevance Health raised its full-year 2026 diluted EPS guidance to at least $20.10 and adjusted diluted EPS guidance to at least $27.00. Additionally, the company increased its FY 2026 operating cash flow guidance to at least $6.0 billion and is accelerating targeted investments.

Elevance Health, Inc. officers expect to speak with investors and analysts this week, reaffirming the company's full-year 2026 shareholders' earnings guidance. The company expects at least $19.85 per diluted share, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, adjusted shareholders' earnings are anticipated to be at least $26.75 per diluted share. Additionally, the full-year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points was reaffirmed.

Elevance Health, Inc. has filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The filing includes the company's unaudited consolidated financial statements, covering balance sheets, income statements, and cash flows. As of April 15, 2026, the company reported 217,162,380 shares of common stock outstanding.

Elevance Health reported first-quarter 2026 results exceeding expectations, with operating revenue reaching $49.5 billion, a 1.5% increase year-over-year. The company raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75, citing underlying business strength and improved visibility. Despite a $935 million accrual for a CMS matter, strong operating cash flow and capital returns to shareholders underscore a positive outlook.